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Abstract: The landscape of the treatment of relapsing–remitting multiple sclerosis is  changing 
fast. Several oral treatments have shown benefit and generate much interest because of the 
convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have 
been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III 
trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor 
with selective immunomodulatory and immunosuppressive properties that have shown consis-
tent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the 
mechanisms of action and efficacy and safety results from clinical trials with this drug. The role 
of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed.
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Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous 
system. Pathologic hallmarks of MS lesions are inflammation, demyelination, axonal 
degeneration, neuronal loss, and gliosis.1
MS initially presents in most patients as a relapsing–remitting condition (RRMS), 
but the majority of RRMS individuals later develop a secondary progressive course.2 
In fewer cases, the disease progresses from the beginning without relapses (primary 
progressive MS) or with rare superimposed relapses (progressive relapsing MS).3
The clinical signs in MS can occur in isolation or in combination and can include 
motor and sensory deficits, partial or complete visual loss, diplopia, impaired coordi-
nation, and gait dysfunction. The diagnosis specifically integrates magnetic resonance 
imaging (MRI) with clinical attacks and paraclinical methods, and implies the dis-
semination of inflammatory activity in time and in space.4
Immunomodulatory drugs used to treat MS decrease the clinical relapse rate and 
accompanying inflammation within the central nervous system. Initially approved 
therapies were all injectable (either subcutaneous or parenteral) and include interferon-β 
(IFNβ), glatiramer acetate (GA), natalizumab, and mitoxantrone.5
The oral drugs emerged from the unmet needs for new mechanistic therapies 
tackling inflammation and disability progression, and for easy and convenient admin-
istration regimens. The latter would translate into an ease of the burden of long-term 
self-administered injections or recurrent intravenous infusions, thus improving quality 
of life and increasing adherence to therapy.6
Currently, five oral therapies have completed Phase III clinical trials (fingolimod, 
laquinimod, dimethyl fumarate, teriflunomide, and cladribine) and have been or are 
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currently in the process of being evaluated by medical agen-
cies in the US and Europe.7–17
In this review, the role of teriflunomide (Aubagio®; 
 Genzyme Corporation, Cambridge, MA, USA) in the man-
agement of MS is discussed. Efficacy data arising from clini-
cal studies will be contrasted with known and potential risks 
in an attempt to place the drug within the new therapeutic 
armamentarium of MS. Currently, Aubagio is marketed in 
the US and Australia and is under review by the European 
Medicines Agency and other regulatory authorities.
Teriflunomide – mechanisms  
of action and pharmacology
Teriflunomide is the active metabolite of leflunomide, 
a drug approved for use in patients with rheumatoid arthritis 
since 1998 (Figure 1).18 Oral leflunomide is almost entirely 
converted into teriflunomide, thus data on leflunomide 
could provide useful information on teriflunomide phar-
macology.19 Teriflunomide has both antiproliferative and 
anti-inflammatory activities exerted through several mecha-
nisms, the main one being inhibition of pyrimidine synthesis, 
and also inhibition of protein tyrosine kinases (Table 1). 
Teriflunomide acts as a reversible inhibitor of a mitochon-
drial membrane protein essential for pyrimidine synthesis 
(dihydroorotate dehydrogenase; DHODH) (Figure 2).20 By 
blocking de novo pyrimidine synthesis, teriflunomide inhibits 
proliferation of autoreactive B-cells and T-cells by cell cycle 
arrest in the G1 phase. However, cellular salvage pathways for 
proliferation exist and allow slowly dividing cell lines such 
as hematopoietic cells, memory cells, and gastrointestinal 
lining cells to sustain ongoing pyrimidine metabolism and to 
survive. Consequently, the potential for significant cytopenia 
is reduced.20 Apart from inhibiting nucleic acids synthesis, 
the reduced availability of pyrimidines could also induce 
impaired generation of lipid messengers and malfunction 
of cell surface molecules, with further immunomodulatory 
consequences.21
Very recently it was suggested that teriflunomide dif-
ferentially modulates the proliferative capacity of antigen 
specific T-cell clones.22 Teriflunomide more efficiently 
blocks the expansion of vigorously proliferating high avid-
ity T-cell clones (that are more dependent on the de novo 
pyrimidine synthesis pathway) than low affinity ones. Thus, 
while in parallel, this will allow normal T-cell homeostasis 
and responsiveness to certain antigens. Indeed, treatment 
with teriflunomide does not impede appropriate immune 
responses to seasonal influenza vaccination, suggesting that 
the memory response to (at least) influenza vaccine is not sig-
nificantly affected by the drug.23 However, since the induced 
degree of lymphopenia is small, it only partially accounts for 
global effects of teriflunomide.24 Moreover, the effects of 
teriflunomide on lymphocyte migration, cytokine production, 
and surface molecule expression persist despite exogenous 
pyrimidine administration.25 Based on in vitro data, it has 
been suggested that the inhibition of protein tyrosine kinase 
(PTK) activity might be another mechanism which mediates 
the immune effects of teriflunomide, although doubts were 
Table 1 Actions of teriflunomide accounting for the effects on 
the immune cells
Inhibition of dihydroorotate dehydrogenase
inhibition of protein tyrosine kinase
inhibition of cyclooxygenase-2
Downregulation of inducible nitric oxide synthase
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Figure 1 Chemical structure of teriflunomide and leflunomide.
Reprinted from Tallantyre et al. The International MS Journal. 2008;15(2):62–68 with 
permission from Cambridge Medical Publications (CMP).20
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Figure 2 Principal mechanisms of teriflunomide.
Reprinted from Tallantyre et al. The International MS Journal. 2008;15(2):62–68 with 
permission from Cambridge Medical Publications (CMP).20
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raised about the very high concentrations required in vivo 
in mice for this activity to take place. However, taking into 
account differences between human and rodent cell lines, 
the immune effects of teriflunomide via PTK inhibition 
might be clinically relevant at therapeutic concentrations 
in humans.26
Supporting PTK inhibition as a mechanism of action 
for the drug, it was demonstrated in animal models that 
teriflunomide may inhibit epithelial growth factor receptor 
tyrosine kinases p56, and p59, which are members of the 
Src-PTK family, and Janus tyrosine kinases jak1 and jak3.27–31 
This would reduce T-cell proliferation and production of 
IFN-γ, interleukin-2, and granzyme B, immunoglobulin G1 
production by B-cells, and inhibit calcium mobilization and 
nuclear factor-κB.29,32
Overall, teriflunomide exerts immunomodulatory effects 
by influencing the function of B-cells and T-cells, and interfer-
ing with the innate immunity.33 Teriflunomide has the potential 
to induce a switch of cytokine profiles from Th1 (proinflam-
matory) to Th2 (anti-inflammatory) as shown in animal and 
human studies.21,34 Stimulation of T-cells in vitro in the pres-
ence of leflunomide led to an increase in anti-inflammatory 
molecules interleukin-1 receptor antagonist and tissue inhibi-
tor of metalloproteinase-1.35 By blocking integrin function at 
different stages of T-cell activation, teriflunomide decreases 
the ability of antigen-presenting cells to activate T-cells and 
stimulate T-cells to activate monocytes.21,26
Teriflunomide may affect T-cell migratory capabil-
ity both in vitro and in vivo and modulate the interaction 
between T-cells and B-cells by inhibiting T-cell-dependent 
antibody production.26,33,36 In addition, teriflunomide may 
act via cyclooxygenase-2 inhibition and may downregulate 
inducible nitric oxide synthase activity in macrophages and 
astrocytes, although the clinical relevance of these effects 
may be limited.37–39 Also, it was recently shown that the 
drug may interfere via a DHODH-independent pathway 
with human monocyte-derived dendritic cell function, but 
without broadly impairing the capacity of dendritic cells 
to regulate adaptive immunity.40 Finally, teriflunomide may 
interfere via DHODH with innate immune system function 
by modulating the expression of adhesion molecules, migra-
tion, and adherence of neutrophils and macrophages, as well 
as controlling proliferation of myeloid progenitors or mast 
cell lines.41 In conclusion, although teriflunomide exerts its 
immunomodulatory effects through a variety of mechanisms 
and has the potential to impede T-cell activation in a mul-
tifaceted manner, DHODH inhibition remains its principal 
mechanism of action.42
Teriflunomide is an open ring malononitrile not related 
structurally to other immunosuppressive compounds and has 
a linear pharmacokinetics profile.36 Pharmacokinetics data 
from eleven studies on healthy volunteers and one study on 
patients with MS receiving teriflunomide shows an absolute 
oral bioavailability close to 100%, with a median time to 
peak plasma concentration of 1–2 hours, delayed by food.43 
The drug is cleared via adrenal and biliary routes with the 
participation of several cytochrome P450 (CYP) enzymes 
and N-acetyltransferase.44
The drug is protein bound above 99% and has a plasma 
half-life of 15–18 days, having only limited penetration across 
the blood–brain barrier.21 Teriflunomide weakly inhibits 
CYP3A and its pharmacokinetics profile is not influenced by 
coadministration with warfarin (a CYP2C9 substrate).43 How-
ever, it can be expected that inducers of CYP3A will accelerate 
teriflunomide elimination, while teriflunomide will prolong 
the half-lives of compounds such as phenytoin, warfarin, or 
nonsteroidal anti-inflammatory drugs which are eliminated 
via CYP2C9.36,45 The clinical significance of most of those 
interactions is not known and needs further study. Recently, it 
was reported that repeated doses of teriflunomide had no effect 
on the pharmacokinetics of warfarin, indicating that terifluno-
mide is not an inhibitor or an inducer of CYP2C9.46 However, 
a 25% decrease in peak international normalized ratio was 
observed when teriflunomide was coadministered with war-
farin, therefore international normalized ratio follow-up and 
close monitoring are recommended.46 Moreover, consideration 
should be given to the type or dose of oral contraceptives 
used in combination with teriflunomide, since the drug may 
increase exposure of ethinyl estradiol and levonorgestrel.
The drug is excreted through feces (37.5%) and urine 
(22.6%), has an elimination half-life of 10–12 days, and is not 
dependent on gender, age, or hepatic impairment.43 The elimina-
tion rate can be accelerated by administration of cholestyramine 
or activated charcoal, particularly useful in situations of over-
dose.43 Dialysis is not effective in removing teriflunomide, as 
recently shown in dialysis patients with rheumatoid arthritis.47
Efficacy studies of teriflunomide  
in experimental models of MS
Teriflunomide has been proven to be effective in experi-
mental models of MS. This was shown initially for lefluno-
mide, which appears to diminish the severity of adoptive 
transfer experimental allergic encephalomyelitis (EAE), 
a monophasic inflammatory demyelinating disease of the 
central nervous system induced by transfer of myelin basic 
protein-specific T-cell blasts.21,25 In experimental  autoimmune 
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neuritis, leflunomide decreased the titers of autoantibod-
ies that developed against myelin proteins and reduced 
the intensity of clinical disease both in a prophylactic and 
therapeutic regimens.24 Some of these effects were inde-
pendent of pyrimidine depletion.24 In an EAE model more 
closely reflecting the clinical course of human RRMS than 
acute monophasic EAE models (the Dark Agouti rat model 
of EAE, characterized by more progressive and sustained 
demyelination and associated axonal loss), various dosages 
of oral teriflunomide delayed disease onset and reduced 
neurological deficits in a dose-dependent manner and 
remained effective in different treatment scenarios.48 The 
prophylactic (ie, administered after the induction of EAE) 
and therapeutic effects of teriflunomide positively impacted 
electrophysiological assessments such as somatosensory 
evoked potential.48 Moreover, spinal cord histology showed 
that teriflunomide administered either therapeutically or as 
prophylaxis significantly led to reduction in axonal loss and 
demyelination by up to 90% and decreased the infiltrates of 
B-cells, T-cells, and macrophages.48 Moreover, teriflunomide 
10 mg/kg administered after EAE induction had a positive 
impact on the number of surviving oligodendrocytes in 
the gracile fascicle.48 Finally, blood–brain barrier integrity 
assessed by MRI was spared for longer with doses of 3 mg/kg 
and completely preserved when higher doses (10 mg/kg) 
were used.48 These robust results from animal studies were 
convincing and encouraging for the initiation of clinical trials 
of teriflunomide in patients with MS.
Clinical studies with teriflunomide
Teriflunomide has different mechanisms of action compared 
to classical first-line disease-modifying therapies (DMTs). 
This creates the premise of its use in MS both as an add-on 
to approved DMTs or as a monotherapy. A comprehensive 
set of trials assessing its efficacy and safety using a range of 
clinical and MRI endpoints have been performed and have 
been previously summarized (Table 2).33 These are presented 
below.
A randomized, controlled Phase II study to determine 
safety and efficacy of teriflunomide monotherapy included 
157 RRMS and 22 secondary progressive MS patients aged 
18–65 years old with an Expanded Disability Status Scale 
(EDSS) score of less than six. Participants were included if 
they had had at least two relapses in the preceding 3 years 
and one clinical relapse during the last year. Subjects were 
randomized to three arms (placebo, teriflunomide 7 mg, 
or teriflunomide 14 mg).49 The trial included a 36-week 
follow-up, with MRI every 6 weeks and clinical assessment 
every 12 weeks. The primary endpoint was the number of 
combined unique active lesions (CUALs), which included the 
number of new T2 lesions, enlarging T2 lesions, and those 
that were gadolinium-enhancing. The secondary endpoints 
included T2 lesion volume, relapse frequency, and EDSS 
change. A total of 160 patients completed the study. Results 
showed a significant reduction in CUAL numbers for both 
the 7 mg/day and 14 mg/day treatment groups versus pla-
cebo (−61%; P , 0.03 and P , 0.01, respectively); a lower 
burden of disease at 36 weeks compared with baseline in 
subjects receiving teriflunomide 14 mg/day (P , 0.02); and 
a smaller proportion of patients with increase in disability 
in the 14 mg/day treatment group (P , 0.04).49 The radio-
logical effects were apparent at 6 weeks, reached statistical 
significance by 12 weeks, and were maintained throughout 
the study. There was a trend toward slower ARRs in the 14 mg 
treatment group versus placebo (77% versus 62%), which did 
not reach statistical significance (P = 0.098). However, the 
study was not sufficiently powered to analyze this second-
ary endpoint. Fewer patients in this group required steroids 
for disease exacerbations (14% versus 23% in the placebo 
arm).49 Overall, treatment was well tolerated, with a similar 
number of adverse events (AEs) and serious AEs for all 
treatment groups.
The factors affecting CUAL decrease were confirmed in 
an open-label extension of the initial trial.50 Moreover, this 
extension confirmed that long-term treatment with terifluno-
mide does not lead to any decline in patient response, as 
reflected by MRI burden and clinical endpoints.51 This was 
observed in patients previously on placebo and switched to 
either 7 mg/day or 14 mg/day, with a greater CUAL decrease 
in the higher-dose group. Patients receiving teriflunomide 
in the original study had no further decrease in CUALs during 
this extension study.50 Relapse rates (0.4 relapses/year) and 
the proportion of patients without relapse during the study 
(54%) were similar in both groups at the end of 144 weeks 
of follow-up.51
Confirming the long-term efficacy, a recent report on 
safety and efficacy outcomes at 8.5 years under teriflunomide 
for 85 patients from the initial extension study showed that 
ARRs remained low while a minimal disability progression 
was observed. A dose-dependent benefit with teriflunomide 
14 mg was noticed for several MRI parameters. The authors 
concluded that the overall safety profile of teriflunomide was 
favorable for up to 8.5 years.52
TEMSO (Teriflunomide MS Oral; NCT00134563) was 
a broader Phase III study of teriflunomide, adopting clinical 
outcomes as primary endpoints in larger populations and 
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with a longer duration of treatment.53 Within a double-blind, 
parallel-group design, 1088 patients with either RRMS or 
progressive relapsing MS were randomized (1:1:1) to receive 
placebo, teriflunomide 7 mg/day, or teriflunomide 14 mg/day 
for 108 weeks.53 To be included in the study, patients had to 
have a maximum EDSS score of 5.5 and either at least one 
relapse during the previous year or two relapses in the previ-
ous 2 years. The primary endpoint was the annualized relapse 
rate (ARR) while secondary endpoints included time to con-
firmed disability progression measured by EDSS and CUALs 
per MRI scan. Both doses of teriflunomide significantly 
decreased the ARR compared with placebo (0.370 ARR 
for 7 mg/day; 0.369 for 14 mg/day; 0.539 for placebo).53 
The relative risk reductions were 31.2% (P = 0.0002) and 
31.5% (P = 0.0005) for 7 mg and 14 mg, respectively. Fewer 
patients receiving teriflunomide experienced disease progres-
sion (21.7% for 7 mg/day; 20.2% for 14 mg/day; 27.3% for 
placebo). However, the relative risk for sustained progression 
was significantly reduced only in the 14 mg group (29.8% 
versus placebo; P = 0.0279).53 MRI scans were performed 
at baseline and at weeks 24, 48, 72, and 108. TEMSO MRI 
results confirmed those of the Phase II study. The number 
of CUALs per scan in the placebo, 7 mg, and 14 mg groups 
was 2.463, 1.288, and 0.76, respectively. This translates into 
a significant relative risk reduction of 47.7% and 69.4% for 
both drug doses (P = 0.001). A significant effect on sustained 
disability progression was observed only in the 14 mg/day 
group.
Teriflunomide was well tolerated; the proportion of 
treatment emergent AEs were similar in all three groups. 
Discontinuation in the trial due to treatment emergent AEs 
occurred at similar rates in all groups and 73.2% of patients 
completed study treatment.53 Importantly, post hoc analyses 
showed that teriflunomide had an impact also on ARR lead-
ing to hospitalization, which was significantly reduced (36% 
with 7 mg, P = 0.015; 59% with 14 mg, P , 0.0001), and the 
annualized rate of emergency medical facility visits for the 
14 mg treatment group (42%, P = 0.004) versus placebo.53
Prespecified subgroup analyses from the TEMSO trial 
have recently been published.54 The objective of these pre-
planned analyses was to determine whether the effects of both 
doses of the drug on relapse rate and disability progression in 
the TEMSO study were demonstrated consistently in a range 
of prespecified patient subgroups related to demographic and 
disease characteristics at baseline.54 The analysis concluded 
that reductions in ARR and disability progression were 
consistently in favor of teriflunomide, with no treatment-
by-subgroup interaction test reaching statistical significance. 
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The effects were homogeneous across all baseline demo-
graphics, clinical, and MRI disease characteristics of all 
the prospectively defined subgroups in the TEMSO study 
population.54
The extension of the TEMSO study offered new infor-
mation on clinical and MRI outcomes 5 years after initial 
randomization.51 The 742 patients who completed the core 
study entered the long-term, double-blind extension, with 
those originally allocated to placebo being re-randomized to 
teriflunomide (7 mg or 14 mg). Five years after randomization 
in the TEMSO study, taking into account the core study and 
extension, the risk of 12-week sustained disability progres-
sion was numerically lower in patients initially treated with 
teriflunomide compared with patients initially on placebo 
(0.371 in the 7 mg/7 mg group compared with 0.420 in 
the placebo/7 mg group and 0.375 in the 14 mg/14 mg 
group compared with 0.418 in the placebo/14 mg group).51 
ARR during the extension period remained low (0.251, 
0.234, 0.182, and 0.206 for placebo/7 mg, 7 mg/7 mg, pla-
cebo/14 mg, and 14 mg/14 mg groups, respectively). Changes 
from baseline in total MRI lesion volume (burden of disease) 
were numerically lower in the 7 mg/7 mg group compared 
with the placebo/7 mg group and were also lower in the 
14 mg/14 mg group compared with the placebo/14 mg group. 
Both doses of teriflunomide were well tolerated and had 
favorable safety over the course of the extension, consistent 
with observations in the core TEMSO study.51 In summary, 
the beneficial effects of teriflunomide on clinical and MRI 
endpoints reported in TEMSO were maintained in the 5-year 
extension study.51 Numerically greater improvements were 
observed in patients who received teriflunomide throughout 
the core study and extension compared with those initially 
assigned to placebo.51
TOWER (Teriflunomide in Patients With Relapsing 
MS; NCT00751881) was the second large Phase III study 
of teriflunomide monotherapy, also evaluating the 7 mg and 
14 mg daily doses of the active drug versus placebo.55 In 
this double-blind, parallel-group trial, 1169 RRMS patients 
were randomized. The inclusion criteria included a maxi-
mum EDSS score of 5.5 at screening, and at least one or 
two relapses in the 12 or 24 months prior to randomization, 
respectively. The study had variable treatment duration 
with a common end at 48 weeks after the last patient was 
randomized. The primary endpoint was again the ARR, while 
the key secondary endpoint was 12-week sustained disability 
progression. Patients treated with 14 mg had a 36.3% reduc-
tion in ARR versus placebo (P , 0.0001) and 31.5% reduced 
risk of 12-week sustained disability progression (P = 0.0442). 
Patients treated with 7 mg had a 22.3% reduction in ARR 
versus placebo (P = 0.02), but there was no significant effect 
of 7 mg on disability progression. Both doses were generally 
well tolerated with similar and manageable safety profiles.55 
Commonly reported treatment emergent AEs with higher 
frequency on teriflunomide included headache, alanine 
aminotransferase elevations, hair thinning, diarrhea, nausea, 
and neutropenia. There were four deaths (placebo: respiratory 
infection; teriflunomide: motor vehicle accident, suicide, 
sepsis).55 The study showed, therefore, that teriflunomide 
significantly reduced ARR and, at the higher dose, disability 
progression. The results confirmed those of TEMSO, further 
supporting the potential value of the 14 mg dose for patients 
with RRMS.55
The above trials have shown that teriflunomide is effective 
and safe in monotherapy. However, other points of interest 
such as how effective teriflunomide is in early RRMS or in 
conjunction with approved DMTs were addressed in other 
trials. Tackling the first issue, TOPIC (Teriflunomide Versus 
Placebo in Patients With First Clinical Symptom of MS; 
NCT00622700) is a randomized, double-blind, placebo-
controlled Phase III study that will investigate the efficacy 
and safety of a 2 year-treatment with teriflunomide 7 mg/day 
and 14 mg/day versus placebo in patients with a first clinical 
episode suggestive of MS (clinically isolated syndrome) in 
the previous 90 days to inclusion.56 The primary endpoint in 
the trial will be the conversion to clinically definite MS and 
its termination date will be mid-2013.
Teriflunomide was also studied as adjunctive therapy 
with either IFNβ or GA in two randomized, double-
blinded,  placebo-controlled Phase II trials. In the first study, 
116 patients with RRMS under a stable dose of IFNβ for 
at least 26 weeks before screening were randomized to 
teriflunomide (7 mg or 14 mg) or placebo for 6 months.57 
Additional inclusion criteria were age 18–55 years, 
a maximum EDSS score of 5.5, clinically stable condition 
for 4 weeks, and lack of relapses for 8 weeks prestudy.57 The 
number and volume of enhancing lesions were reduced in 
both teriflunomide groups versus placebo (7 mg: 56% and 
14 mg: 81%; P , 0.001) and a greater proportion of patients 
remained free of enhancing lesions during the treatment (pla-
cebo: 57.9%, 7 mg: 69.4%, and 14 mg: 81.6%).57 Of the 116 
RRMS patients that were initially randomized to treatment 
for 6 months, 86 continued for a further 6 months (placebo: 
31; 7 mg: 28; 14 mg: 27 patients). Evaluations included 
treatment emergent AEs, laboratory data, and brain MRI. In 
both teriflunomide arms, enhancing lesions were reduced, 
with relative risk reductions of 84.6% (P = 0.0005) and 
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82.8% (P , 0.0001) in 7 mg and 14 mg groups, respectively, 
versus placebo. Enhancing lesion volume was reduced by 
46% for 7 mg (P = 0.059) and 66% for 14 mg (P = 0.123).57 
A trend toward dose-dependent reduction in ARR was also 
noted (RRRs 32.6%, P = 0.4 and 57.9%, P = 0.1005 for 7 mg 
and 14 mg, respectively). The authors concluded that the 
addition of teriflunomide to stable-dosed IFNβ significantly 
improved disease control evaluated by MRI activity beyond 
IFNβ alone, with a trend to a reduction in clinical relapse, 
and good safety and tolerability.57
A similar design was used for the Phase II study evaluat-
ing teriflunomide added to a stable dose of GA.58 A total of 
123 patients with relapsing MS already receiving GA were 
randomized to once-daily 7 mg or 14 mg teriflunomide ther-
apy or placebo. Again, the EDSS at screening had to be less 
than or equal to 5.5, the GA dose stable for at least 26 weeks 
prior to the study, and patients should have been clinically 
stable for 4 weeks prior to randomization and without relapses 
in the preceding 60 days prior to randomization.58 Compared 
to placebo, the number and volume of gadolinium-enhancing 
lesions were reduced in the 7 mg group (P = 0.011) and in 
the 14 mg group (P = 0.039). Overall, the addition of teri-
flunomide to GA improved disease control compared with 
GA therapy alone.58
Currently, a Phase III trial (TERACLES, Terifluno-
mide in Patients With Relapsing MS and Treated With 
IFNβ; NCT01252355) studying the effects of teriflunomide 
as an add-on in RRMS patients treated with IFNβ is cur-
rently  ongoing.59 Patients should have been on a stable dose 
of IFNβ for at least 6 months prior to screening and have 
disease activity (clinical relapse or MRI enhancing lesions) 
in the 12 months prior to randomization and after the first 
3 months of IFNβ treatment.59 The primary objective of the 
trial is to assess the effect of teriflunomide in comparison 
to placebo on ARR in RRMS patients treated with IFNβ. 
Secondary objectives are disease activity as measured by 
MRI, disability progression, safety, and tolerability as add-
on therapy; pharmacokinetics of teriflunomide; associations 
between variations in genes and clinical outcomes; fatigue 
and health-related quality of life; and measures of health eco-
nomics (hospitalization due to relapse, including the length 
of stay and any admission to the intensive care unit).
Recently, the results of the first Phase III trial study-
ing teriflunomide compared to a first-line DMT have been 
published.60 TENERE (Teriflunomide and IFNβ-1a in Patients 
With Relapsing MS; NCT00883337) was a multicenter, ran-
domized, parallel-group, rater-blinded study comparing the 
effectiveness and safety of teriflunomide and  subcutaneous 
IFNβ-1a in patients with RRMS with a maximum EDSS score 
of 5.5 at baseline.60 The patients (n = 324) were randomized to 
receive once-daily teriflunomide (7 mg or 14 mg) or IFNβ-1a 
(albumin-free formulation, three times weekly). The study 
had a fixed end; the approximate range of treatment duration 
for completers was 48–114 weeks. The primary endpoint was 
time to failure – defined as the first occurrence of confirmed 
relapse or permanent treatment discontinuation for any rea-
son, whichever came first.60 Secondary endpoints included 
ARR, Fatigue Impact Scale score, and Treatment Satisfaction 
Questionnaire for Medication (TSQM) score. There was no 
statistical superiority for the primary endpoint when compar-
ing the two teriflunomide groups with IFNβ-1a. The propor-
tion of patients with failure was 48.6%, 37.8%, and 42.3% 
for teriflunomide 7 mg, 14 mg, and IFNβ-1a respectively. 
The rate of permanent treatment discontinuation was lower in 
both teriflunomide groups than in the IFNβ-1a group (18.3%, 
19.8%, and 28.8%). No difference was detected in the adjusted 
ARRs between the teriflunomide 14 mg and IFNβ-1a groups 
(0.259 and 0.216, respectively), but the rate was higher in the 
teriflunomide 7 mg group (0.410).60 Patients receiving either 
dose of teriflunomide reported a higher least-squares mean 
TSQM global satisfaction score, indicating better satisfac-
tion than when treated with IFNβ-1a.60 Both teriflunomide 
doses were well tolerated, with no unexpected safety signal 
identified. The authors concluded that although no statistical 
superiority was observed when comparing the two terifluno-
mide groups and IFNβ-1a on the primary composite endpoint 
the rate of permanent, treatment discontinuation was lower 
in both teriflunomide groups than in the IFNβ-1a group, thus 
making teriflunomide a candidate for first-line treatment in 
RRMS.60
Safety profile for teriflunomide
Safety data and postmarketing AEs of leflunomide, now 
licensed for use in rheumatoid arthritis for more than 
a decade, are useful in defining the safety profile for 
 teriflunomide.61 Leflunomide may cause liver damage; 
liver function tests are required prior to initiating therapy, 
then monthly for the first 6 months of treatment, and then 
every 6–8 weeks thereafter.36 Three cases of progressive 
multifocal leukoencephalopathy have been reported (two 
cases in patients with rheumatoid arthritis and one in a 
patient with systemic lupus erythematosus), two of whom 
received immunosuppressive drugs prior to leflunomide.62–64 
 However, no data exist that links teriflunomide use with pro-
gressive multifocal leukoencephalopathy. The occurrence 
of interstitial lung disease has been reported in rheumatoid 
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arthritis patients being treated with leflunomide who have 
preexisting pulmonary conditions or are on premedica-
tion with methotrexate.65 In animal studies, leflunomide 
demonstrated a degree of reproductive toxicity, although 
a study of 64 pregnancies in women exposed to lefluno-
mide observed no significant differences in the overall 
rate of structural birth defects compared to nonexposed 
 pregnancies.66 However, in practice it is recommended 
that women of childbearing age under leflunomide utilize 
effective methods of contraception.67
The place of teriflunomide in MS therapy is strongly 
dependent on the safety and tolerability characteristics. Here, 
some of the issues regarding the biological, somatic, and 
teratogenic side effects of the drug will be briefly reviewed. 
As mentioned earlier, in teriflunomide trials AEs were 
distributed equally across all treatment and placebo groups 
(Table 3). Common adverse effects of teriflunomide include 
gastrointestinal symptoms (diarrhea, dyspepsia, nausea, 
vomiting, abdominal pain, and oral ulcers), increased levels 
of liver enzymes, skin rashes, weight loss, hair thinning, 
infections, and hypertension.53
In the Phase II trial of teriflunomide as monotherapy, 
despite the decrease in leukocytes seen in the active drug 
groups, infection rates were similar among drug and placebo 
groups and there were no discontinuations of therapy owing 
to leukopenia.49 However, a higher rate of infections in treated 
patients was seen when teriflunomide was combined with 
IFNβ, but not in combination therapy with GA.33 In the TEMSO 
study, mean reductions in lymphocyte and neutrophil counts 
were small (#15%) and reversible after treatment discontinu-
ation, or even on treatment.68 Overall, no other clinically 
significant complications to blood cytopenias were reported.68
In clinical trials, teriflunomide does appear to elevate 
alanine aminotransferase to a greater degree than placebo. 
However, in both the Phase II trial and TEMSO, the clinically 
significant elevations in hepatic transaminases were similar 
between placebo and treatment groups.49,53
Discontinuation rates in the TEMSO trial were 25% and 
27% in the treatment group (for 7 mg and 14 mg, respec-
tively) and 29% in the placebo arm. The incidence of AEs 
was considered to be similar across the groups in the TEMSO 
study. Neither serious AEs (12.8% versus 14.1%) nor serious 
AEs leading to treatment discontinuation (8.1% versus 9.8%) 
were found to be significantly different between the tested 
doses of teriflunomide.53
Recent data on cessation of leflunomide in patients 
with rheumatoid arthritis suggest that differences in genes 
associated with the metabolism, clearance, and efficacy of 
leflunomide may play a role.69 In particular, the CYP2C19 
phenotype was associated with cessation due to toxicity. 
Since CYP2C19 intermediate and poor metabolizers have 
lower teriflunomide concentrations, it was suggested that 
those patients were having a poor risk/benefit ratio when 
using the drug.69
The current approval for Aubagio contains a boxed warn-
ing to alert prescribers and patients to the risk of birth defects. 
Therefore, the drug is labeled as Pregnancy Category X, 
which means women of childbearing age must have a nega-
tive pregnancy test before starting the drug and use effective 
birth control during treatment. Study data showed that oral 
contraceptives maintained their efficacy with concurrent 
teriflunomide coadministration and didn’t affect the drug’s 
pharmacokinetics.33 As with leflunomide, women wishing to 
become pregnant should undergo a washout period with either 
cholestyramine or activated charcoal after stopping treatment 
with teriflunomide.33 If a pregnancy is planned, plasma levels 
of teriflunomide have to be below 0.02 mg/L in two separate 
tests 14 days apart. In the absence of washout procedure, 
due to the pharmacological profile of teriflunomide and the 
individual variations in drug clearance, it may take up to 
2 years to reach those plasma levels.49
Pregnancy outcomes from the teriflunomide clinical 
development program were reported recently.70 The data were 
extracted from a retrospective analysis of seven terifluno-
mide clinical trials and included a total of 65 pregnancies, 
43 of which were under teriflunomide. Upon learning of her 
pregnancy, the patient was instructed to discontinue the drug 
and go through an elimination procedure (cholestyramine or 
activated charcoal). The reported outcomes of the 43 pregnan-
cies in teriflunomide-treated patients were: induced abortion 
(n = 20); spontaneous abortion (n = 8); healthy newborn 
(n = 12); ongoing pregnancy (n = 2); and outcome pending in 
one case.70 No structural or functional deficits were reported 
Table 3 Most common adverse events and their incidence (%) in 
Phase II and Phase III trials with teriflunomide49–51
Adverse event Incidence
Alanine aminotransferase increase 12%–14.2%
Headache 19%–25%
Nasopharyngitis 21%–26%
Diarrhea 8%–17.9%
Alopecia 12%–15%
Fatigue 10%–14.5%
Nausea 9%–13.7%
Urinary tract infection 7.3%–11%
Reprinted from Degenerative Neurological and Neuromuscular Disease, volume 2, 
Nwankwo E, Allington DR, Rivey MP, Emerging oral immunomodu lating agents – focus 
on teriflunomide for the treatment of multiple sclerosis, pages15–28, Copyright © 
2012, with permission from Dove Medical Press Ltd.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
548
Tanasescu et al
Neuropsychiatric Disease and Treatment 2013:9
in newborns with prenatal teriflunomide exposure following 
drug elimination. More prospective data are needed with 
respect to pregnancy outcomes and teriflunomide.70
Other undesirable effects have been reported in clinical 
studies using teriflunomide. In the pooled placebo-controlled 
trials, hair loss or thinning was more common with teri-
flunomide than with placebo, but in the majority of patients 
it was mild (76%) and recovered without sequelae (85%).71 
The risk of hair loss and thinning was highest during the first 
6 months of treatment, and overall less than 1% of patients 
discontinued treatment. Most cases resolved spontaneously 
without complication and without the need for hair loss treat-
ment while the patient remained on teriflunomide.71
Place of teriflunomide in MS therapy
The development of oral therapies in MS presents not only 
opportunities and options, but also challenges. Oral agents 
as effective as, or more effective than the currently available 
injectable therapies would be a welcome advance in MS 
therapy. However, efficacy, safety, and tolerability are impor-
tant in determining the new MS therapeutic armamentarium 
(Table 4). The impact of new drugs could finally translate 
into a better quality of life for the patient by both reducing 
(ideally eliminating) disease activity and providing a better 
patient satisfaction. The ease of administration would be an 
important point in favor of oral drugs, since up to 90% of MS 
patients using subcutaneous formulations of IFNβ and up to 
33% for those using an intramuscular formulation experience 
some form of localized injection-site reaction.72 The use of 
an oral drug such as teriflunomide may improve adherence 
and reduce restrictions on lifestyle.
It is still to be determined how the newer drugs should 
be used relative to the time-tested injectable DMTs, how 
DMTs sequence should be determined, whether drugs 
should be used in combination, and how benefit/risk ratios 
for individual drugs will be compared in different MS 
populations.73
Teriflunomide has a definite place within the increasing 
number of options for MS drugs. Efficacy, safety, and patient 
perspectives versus other oral therapies will determine its 
use. A survey fielded in March 2012 including 299 RRMS 
patients treated with first-line DMTs in the US showed that 
MS patients rate their current DMTs higher compared to 
neurologists but would expect new DMTs to be more con-
venient, safe, and tolerable.74,75
The extensive clinical development program for terifluno-
mide constitutes one of the widest programs of any of the new 
oral DMTs. Since the efficacy of teriflunomide is comparable 
to IFNβ and GA, patient-focused perspectives such as quality 
of life, patient satisfaction, adherence, and uptake would be 
crucial when choosing between the drug classes.
Once-daily teriflunomide is safe and well tolerated and its 
morbidity appears low. Data from the TEMSO trial showed 
that teriflunomide had the same impact as placebo on a utility 
score derived via a standardized health-related quality of life 
questionnaire administered during the study. This means that 
the drug was well-tolerated and displayed a favorable safety 
profile during the trial.76
Table 4 Oral drugs for relapsing–remitting multiple sclerosis
Compound Mechanism  
of action
Major trials ARR RR MRI  
lesions RR
Dosing  
regimen
Common AEs
Teriflunomide Lymphocyte 
antiproliferation
TEMSO, TENERE  
TOPiC, TERACLES
.30% CUALs 60% Once daily ↑LFTs, neutropenia, nasopharyngitis, 
alopecia, nausea, paresthesia, diarrhea, 
arthralgia, back and limb pain
Fingolimod Lymphocyte 
sequestration
FREEDOMS 
TRANSFORMS
.50% Gd+ 
lesions 60%
Once daily Lymphocytopenia, serious viral 
infections, ↑LFTs, bradycardia,  
Av block, macular edema, cancers
Laquinimod Th1 toTh2 shift ALLEGRO,  
BRAvO
.20% CUALs ∼40% Once daily ↑LFTs, chest pain, back pain, 
abdominal pain, viral infections, 
menometrorrhagia with myofibroma, 
exacerbation of preexisting glaucoma
BG12 Activation  
of Nrf2 pathway
DEFiNE,  
CONFiRM
.51% Gd+  
lesions ∼70%
Three times  
daily
Flushing, headache, nausea, 
nasopharyngitis, pruritus, ↑LFTs
Reprinted from Degenerative Neurological and Neuromuscular Disease, volume 2, Nwankwo E, Allington DR, Rivey MP, Emerging oral immunomodu lating agents – focus on 
teriflunomide for the treatment of multiple sclerosis, pages15–28, Copyright © 2012, with permission from Dove Medical Press Ltd.
Abbreviations: AE, adverse event; ALLEGRO, Assessment of Oral Laquinimod in Preventing Progression of Multiple Sclerosis; ARR, annual relapse rate; Av, atrioventricular; 
CONFiRM, Oral BG12 versus Copaxone in Relapsing–Remitting Multiple Sclerosis; CUAL, combined unique active lesion; DEFiNE, Oral BG12 versus Placebo in Relapsing–
Remitting Multiple Sclerosis; FREEDOMS, Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis; Gd+, gadolinium positive; LFT, liver function test; MRi, magnetic 
resonance imaging; RR, relative reduction; TEMSO, Teriflunomide Multiple Sclerosis Oral; TENERE, Teriflunomide and Interferon-β-1a in Patients with Relapsing Multiple 
Sclerosis; TERACLES, Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-β; TOPIC, Teriflunomide Versus Placebo in Patients With 
First Clinical Symptom of Multiple Sclerosis; TRANSFORMS, Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis with Optional Extension Phase.
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In the TENERE study, the effects on patient satisfaction 
were compared between teriflunomide and subcutaneous 
IFNβ.77 Patients receiving any of the doses of teriflunomide 
reported higher TSQM scores (higher score indicating greater 
satisfaction) for effectiveness (7 mg, P = 0.02 and 14 mg, 
P = 0.27 versus IFNβ), side effects (P , 0.0001 for both 
doses versus IFNβ), and convenience (P , 0.0001 for both 
doses versus IFNβ) after 48 weeks of treatment.77 Moreover, 
the least-squares mean changes from baseline in the Fatigue 
Impact Scale total score at week 48 (positive change indi-
cating a worsening) were in favor of teriflunomide.77 The 
combined least-squares mean and TSQM global satisfaction 
score at week 48 was again in favor of teriflunomide: 68.292 
(P = 0.02 versus IFNβ) for 7 mg/day; 68.818 (P = 0.01) for 
14 mg/day; and 60.975 for IFNβ. The authors concluded that 
teriflunomide-treated patients expressed greater satisfaction 
with treatment than those who received IFNβ.77
Convenience and patient preference may be the factors 
which may diminish the use of the injectable drugs as first-line 
treatment and lead to an increase in the use of oral compounds. 
The long-term safety profile of IFNβ and GA would argue 
for keeping those drugs as first-line DMTs; however, the liver 
toxicity of teriflunomide does not seem to be significantly dif-
ferent from fingolimod and IFNβ preparations. Teriflunomide 
would therefore be an option for patients who have used 
DMTs in the past and discontinued use because of side effects. 
Moreover, some patients with mild disease who are not using 
an injectable DMT might elect to use a convenient oral drug 
with a favorable safety profile such as teriflunomide.73 Also, 
teriflunomide might be an option for the proportion of patients 
already using injectable drugs who have breakthrough disease, 
are needle-phobic, or do not tolerate injectable compounds 
because of side effects.
For treatment-naive patients with RRMS, use of oral 
drugs such as teriflunomide as first-line treatment would 
correspond strongly with perceived safety. Finally, patients 
with  clinically isolated syndrome would present a spe-
cial challenge in the new era of emerging oral therapies. 
 Teriflunomide could be one the drugs of choice if results 
from the TOPIC trial demonstrate its efficacy for this cat-
egory of patients.
Future studies may clarify if teriflunomide is an option 
in patients with prolonged exposure to natalizumab who 
have John Cunningham virus antibodies, although the risk 
of disease activation after discontinuation of natalizumab is 
a concern.73
Teriflunomide seems to have (despite the lack of 
direct comparisons) lower effectiveness than the other 
oral compounds. Fingolimod and BG12 reduce relapses ver-
sus placebo by 54% and 53%, respectively.8,14 Nevertheless, 
teriflunomide is easier to use than fingolimod, since there is 
no need for first-dose monitoring, no risk of macular edema 
or cardiac complications, and the washout period for the 
drug is shorter than for fingolimod (45 days for the latter). 
Therefore, teriflunomide may turn out to be an additional 
choice for MS patients.
An important aspect of the safety prof ile of teri-
flunomide in comparison to other oral agents is the long 
follow-up in studies (currently up to 8.5 years), enough to 
spot the development of opportunistic infections. How-
ever, since teriflunomide interferes with T-cell function, 
the occurrence later in time and when used more exten-
sively in broader populations of infectious events cannot 
be excluded.  However, appropriate immune response to 
infectious triggers and vaccinations could be normal under 
teriflunomide.23  Nevertheless, in the case of an acute infec-
tious event, teriflunomide can be washed out of the system 
relatively quickly, thereby allowing the immune system to 
react fully to the infectious aggression. Long-term follow-
up in larger MS populations could provide data on the 
potential of opportunistic infections and other conditions 
that have been associated with leflunomide.
Defining the best responder profile to teriflunomide is a 
challenge for future studies. Individual genetic or clinical 
features might predict an optimal response to teriflunomide 
for a given patient at some stage of the disease. Careful 
follow-up and pharmacogenomic studies might prove helpful 
in identifying an ideal candidate for teriflunomide.73
Currently, taking into account the immune model of 
MS pathogenesis and its proposed mechanism of action, 
teriflunomide may be most effective between the early stage 
of the disease and the relapsing–remitting stage and early 
during the latter stage – at a time when immune processes 
and linked inflammatory activity may be controlled – and as 
an alternative to injectable treatments.78
The landscape of MS treatments is changing fast. With 
the approval of new therapies and as information and expe-
rience accumulates, dramatic changes in MS therapeutic 
management are expected in the next 3 years. The choice 
between DMTs in MS will certainly depend upon efficacy 
and safety, but also on cost. In the US, teriflunomide currently 
costs $45,000 a year per patient, while Copaxone® costs 7% 
more, Avonex® 8% more, and Gilenya® 28% more. MS drugs 
are some of the most expensive therapies on the market and 
recent studies show that health gains MS patients get from 
their medications come at an extremely high cost.79
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The role and place of oral teriflunomide in MS therapy 
will therefore depend upon, and be influenced by, the results 
of long-term safety studies in wider populations and of com-
parator trials; on strategies allowing comparisons of treatment 
effects in large observational databases, such as propensity 
score-based methods; and on the information about the man-
agement of patients treated with the drug.80,81
Nevertheless, the approval of teriflunomide as the second 
oral DMT in MS is a step forward to better care and therapy 
management of this disabling condition.
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